Entries by Thomas Gabrielczyk

Roche’s Alecensa approved in China

Roche AG’s ALK blocker Alecensa (alectinib) has been granted market approval by China National Drug Administration as first line NSCLC monotherapy in patients with ALK-positive non small cell lung cancer (NSCLC)

New lupus target unraveled

EGFR agonists support the protective effect of Langerhans against UV-induced damage of skin cells, a hallmark of lupus erythematosus and other autoimmune and dermatologic conditions, a team of US and […]

Researchers remyelinate neurons

German neurogenetics at the Max-Planck-Institute for Experimental Medicine have cured the rare incurable hereditary Charcot-Marie-Tooth disease by simply supplementing the food of mice carrying the disease-causing duplication of the PMP22 gene with […]